TD Asset Management
CTMX icon

TD Asset Management’s CytomX Therapeutics CTMX Stock Holding History

TD Asset Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-78,821
Closed -$609K – 1529
2021
Q1 		$609K Buy
+78,821
New +$624K ﹤0.01% 1368
2019
Q4 		– Sell
-35,182
Closed -$260K – 1403
2019
Q3 		$260K Sell
35,182
-11,400
-24% -$112K ﹤0.01% 1269
2019
Q2 		$523K Hold
46,582
– – ﹤0.01% 1177
2019
Q1 		$501K Sell
46,582
-13,900
-23% -$205K ﹤0.01% 1189
2018
Q4 		$913K Sell
60,482
-4,400
-7% -$65.3K ﹤0.01% 1078
2018
Q3 		$1.2M Buy
64,882
+17,682
+37% +$403K ﹤0.01% 1121
2018
Q2 		$1.08M Buy
47,200
+3,700
+9% +$94.5K ﹤0.01% 1112
2018
Q1 		$1.24M Buy
+43,500
New +$1.24M ﹤0.01% 1005

Other funds holding CTMX

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

TD Asset Management's CTMX Position: Q2 2021 in Review

TD Asset Management sold out of CytomX Therapeutics (CTMX) in Q2 2021, closing a stake of 78,821 shares — an estimated $609K sold.

TD Asset Management first reported a position in CTMX in Q1 2018 and held it in 8 quarters. The position peaked at $1.24M in Q1 2018. 122 funds tracked by Wall St. Rank hold CTMX as of Q2 2021.

  • TD Asset Management reported no remaining CytomX Therapeutics position as of Q2 2021 after selling out during the quarter.
  • TD Asset Management sold 78,821 CytomX Therapeutics shares in Q2 2021, an estimated $609K.
  • TD Asset Management first reported a position in CytomX Therapeutics in Q1 2018 and held it in 8 quarters.
  • TD Asset Management's CytomX Therapeutics position peaked at $1.24M in Q1 2018.
  • 122 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2021.

Based on TD Asset Management's 13F filing for Q2 2021, filed 11 Aug 2021.